Danaher Corporation (DHR) has notable oscillation in the market, with multiple entities increasing and decreasing their stakes in the company. Global Trust Asset Management, Capital Advisors Inc., Aberdeen Group, Bank Pictet & Cie Europe AG, Nisa Investment Advisors, Allspring Global Investments, and Triad Investment Management among others have augmented their positions. Conversely, Tritonpoint Wealth, Beacon Investment Advisory Services, James Hambro & Partners and DAVENPORT & Co have disposed of some of their shares. UBS has reduced its price target for DHR, albeit maintaining a 'Buy' rating. Despite a downward trend in the company's stock price, a target of $239 is still projected by analysts. DHR also showcased a revenue growth projection at TD Cowen 46th Annual Health Care Conference. Indicators of a strong strategic fit with Masimo Deal and robust free cash flow expectations were noted. A growing focus on the bioprocessing business and AI initiatives were other highlights. There are however questions about the company's fundamentals and insiders possibly breaching fiduciary duties.
Danaher Corporation DHR News Analytics from Wed, 13 Aug 2025 07:00:00 GMT to Sat, 04 Apr 2026 12:07:05 GMT -
Rating 2
- Innovation 4
- Information 7
- Rumor -3
